MedTrace Logo

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

NCT00314210 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 575

Last updated 2009-03-25

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD).

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Conditions

  • Anxiety Disorders

Interventions

DRUG

Quetiapine SR

Sponsors & Collaborators

Principal Investigators

  • Martin Brecher, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-08-31

Countries

  • United States
  • Australia
  • Canada
  • Finland
  • Germany
  • Hungary
  • Indonesia
  • Philippines
  • Russia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00314210 on ClinicalTrials.gov